TI
KRON

Trexquant Investment’s Kronos Bio KRON Stock Holding History

Trexquant Investment’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-46,002
Closed -$333K – 1694
2022
Q1 		$333K Buy
+46,002
New +$392K 0.02% 949
2021
Q4 		– Sell
-9,902
Closed -$208K – 1477
2021
Q3 		$208K Buy
+9,902
New +$213K 0.02% 942

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Trexquant Investment's KRON Position: Q2 2022 in Review

Trexquant Investment sold out of Kronos Bio (KRON) in Q2 2022, closing a stake of 46,002 shares — an estimated $333K sold.

Trexquant Investment first reported a position in KRON in Q3 2021 and held it in 2 quarters. The position peaked at $333K in Q1 2022. 93 funds tracked by Wall St. Rank hold KRON as of Q2 2022.

  • Trexquant Investment reported no remaining Kronos Bio position as of Q2 2022 after selling out during the quarter.
  • Trexquant Investment sold 46,002 Kronos Bio shares in Q2 2022, an estimated $333K.
  • Trexquant Investment first reported a position in Kronos Bio in Q3 2021 and held it in 2 quarters.
  • Trexquant Investment's Kronos Bio position peaked at $333K in Q1 2022.
  • 93 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2022.

Based on Trexquant Investment's 13F filing for Q2 2022, filed 11 Aug 2022.